Home » Newsletters » BioWorld Science

BioWorld Science

May 3, 2006

View Archived Issues

E1 vaccination evaluated in patients with hepatitis C genotype 1 infection

Satavaptan improves hyponatremia in cirrhosis patients

Studies in vivo reveal anti-hepatitis C virus effects of DEBIO-025

Novel plant-derived CDK inhibitor halts HeLa cell growth

Adherex begins proof-of-mechanism trial for eniluracil

Enrollment open in phase I/II study of Chemophase with mitomycin

PMA submission for 2.25 mm Cypher Stent

Alexza initiates AZ-003 phase I study

New preclinical data further elucidate talabostat's dual mechanism of action

CardioVascular BioTherapeutics begins clinical studies in chronic lower back pain

Preclinical profile of L-870812 presented

AstraZeneca presents a new glucokinase activator

Pre-NDA meeting for AzaSite

First interim analysis data from phase IIIb mesothelioma study of Onconase

Treatment begins in pediatric phase III study of nimotuzumab

Final survival results from phase IIb study of Stimuvax

AmpliMed studies benzimate in patients with advanced refractory cancer

Phase III protocol agreed upon for OncoVAX in Stage II colon cancer patients

ApoB-100-specific ASO more effective than MTTP-specific ASO in lowering cholesterol in mice

Antifungal BAL-8557 awarded fast track designation

Wex updates status of Tectin program

FibroGen licenses oral HIF-PH inhibitors to Astellas

Pharmacokinetics, safety and activity of pradefovir reported

PEP-005 Topical gel clears superficial basal cell carcinoma in study

Cipralex filed in Sweden for obsessive compulsive disorder

Acomplia recommended for approval in E.U.

BMS discontinues commercialization of Tequin

Betaferon recommended for early use in MS patients in E.U.

Recent patents claim novel therapeutic agents for ocular disorders

New treatment options reported for disorders associated with blood coagulation

Novel nicotinic receptor agonist demonstrates preclinical antiinflammatory activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...